Celldex Therapeutics, Inc. engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27.
